New drug combo aims to outsmart tough stomach cancers
NCT ID NCT07432295
Summary
This study is testing if adding an experimental drug called givastomig to standard immunotherapy and chemotherapy works better for controlling advanced stomach or esophageal cancer. About 180 adults whose cancer has spread and who have not yet received treatment for their advanced disease will participate. Researchers will compare how long patients' cancer stays under control with the new combination versus the standard treatment alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
I-MAB Site 1005
RECRUITINGDuarte, California, 91010, United States
Contact
-
I-Mab Site 1013
RECRUITINGSugarland, Texas, 77479, United States
Contact
-
I-Mab Site 1016
RECRUITINGGoodyear, Arizona, 85338, United States
Contact
Conditions
Explore the condition pages connected to this study.